Metastatic Breast Cancer Report 2025 (NAoMe/NATCAN)
The National Audit of Metastatic Breast Cancer (NAoMe), part of the National Cancer Audit Collaborating Centre (NATCAN), has published a report on care received by people diagnosed with metastatic breast cancer (MBC) between 1 January 2020 and 31 December 2022 in England and Wales. It found that the percentage of patients who survived for at least one year was 65%, and for three years was 44% (England and Wales combined, where metastatic disease was identified at the time of initial diagnosis).
59% of patients in England and 70% in Wales, whose cancer was identified as metastatic at initial diagnosis, had documented multidisciplinary team discussions
In addition to two recommendations to improve data quality, this report makes three clinical recommendations:
- Ensure the care for all people newly diagnosed with MBC is discussed within a breast multidisciplinary team (MDT) meeting
- Examine rates of a particular treatment recommended by NICE where there is high variation across the country
- Assess 30-day mortality rates following chemotherapy and, in Trusts with rates far from the national average, conduct outcome reviews and evaluations of local prescribing practices to ensure appropriate consideration of chemotherapy risks and benefits.
Read the full report: You can view the report by clicking the button below.
Stay up-to-date: For notifications of future reports from HQIP, sign up to our mailing list.
More cancer reports: This month, HQIP has published 7 reports on cancer care – to see all others, go to our reports page.
More information: For further information and related reports, go to the programme page on this website.
